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Summary
Objective: To analyze human articular chondrocyte cell-associated matrix aggrecan, hyaluronan (HA) and type II collagen metabolism using
flow cytometry, and to compare the results obtained for aggrecan with classic 35Sulfate incorporation methods and an enzyme linked
immunosorbent assay (ELISA).
Design: Human articular chondrocytes obtained from five donors were cultured in gelled agarose and tested for their response to different
concentrations of interleukin-1 (IL-1). Synthesis and distribution of aggrecan in the cell-associated matrix (CAM), in the interterritorial
matrix and in the nutrient medium of the chondrocytes in culture were analyzed using 35Sulfate incorporation. The results were expressed
as pg SO4 incorporated in aggrecan per 1×106 cells/h. Flow cytometry with FITC-conjugated monoclonal antibodies against aggrecan and
type II collagen, and with the biotinylated hyaluronic acid binding protein (b-HABP), was used to investigate the synthesis and accumulation
of aggrecan, type II collagen and HA in the CAM of the cultured cells. The packing of these macromolecules in the CAM of the chondrocytes
was assessed by measuring the mean fluorescence intensity (MFI) of the cell sample due to the binding of the specific monoclonal antibodies
or b-HABP used. ELISA was used in parallel to quantify CAM aggrecans after these macromolecules were brought into solution with
guanidinium chloride. Detection of aggrecan by flow cytometry was compared with 35S-incorporation in chondrocytes from two subjects and
with ELISA in a further two donors.
Results: IL-1 suppressed aggrecan synthesis by chondrocytes in agarose. An IL-1 dose-dependent suppression of 35S-aggrecan in the
CAM reflected the changes in the interterritorial matrix. IL-1-induced aggrecan breakdown was followed by a rise in 35S-aggrecan
metabolites in the incubation media of the cells in culture. Flow cytometry and ELISA confirmed this decreased accumulation of aggrecan
in the CAM of the chondrocytes. The results obtained with flow cytometry were closely related to those obtained with ELISA.
35S-incorporation, on the other hand, indirectly measures the glycosaminoglycan content of the aggrecan and does not necessarily reflect
the absolute amount of aggrecan molecules. Therefore, the effects of IL-1 on cell-associated aggrecan, where assessed with
35S-incorporation, did not correlate with the results of the flow cytometric assays. Flow cytometry enabled the detection of an impaired
synthesis and accumulation of HA and of type II collagen in the CAM of the cultured chondrocytes. IL-1-induced changes in CAM aggrecan
and hyaluronan closely agreed.
Conclusions: Flow cytometry offers an efficient tool to study the metabolism of the chondrocyte CAM. The MFI has been used as a parameter
to quantify the ECM molecules in the CAM. © 2001 OsteoArthritis Research Society International
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Human articular cartilage is characterized by a sparse
population of chondrocytes embedded in an abundant
extracellular matrix (ECM). The ECM in adult cartilage is
organized in several compartments1. The pericellular
matrix, immediately adjacent to the chondrocyte plasma
membrane, consists of a large amount of large
proteoglycan/aggrecan aggregates and relatively fewer
organized fibrillar collagens. Aggrecan aggregates bind to
the cell via the interaction of hyaluronan (HA)2 and possibly
of chondroitin-sulfate3,4 with CD44-like receptors. Con-
tiguous to the pericellular matrix lies the territorial matrix,454which is composed of a basket-like network of cross-linked
fibrillar collagen, associated with the chondrocytes through
specific matrix molecules, such as annexin V5 and integrin
216. These two compartments define the cell-associated
matrix (CAM). Chondrocytes exert an active metabolic
control over the CAM, whereas the interterritorial matrix
(ITM), which is located further from the cell membrane
and which contains most of the collagen fibrils and
aggrecans7,8, is more metabolically inert.
In the normal joint there is a balance between the
continuous processes of cartilage matrix degradation and
repair. In some inflammatory conditions this homeostatic
state is disrupted and the catabolic processes by chondro-
cytes are increased. Proinflammatory cytokines are
responsible for the catabolic process occurring in the
pathological tissues. These biologic mediators appear to
be released by the cells in the synovial membrane and
diffuse into the cartilage, where they activate the chondro-
cytes. Interleukin 1 (IL-1) is considered to be the major
cytokine inducing catabolic processes in cartilage. IL-1
stimulates the expression of metalloproteinases (MMPs)
and tissue plasminogen activator (tPA)9, and in parallel
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ISOLATION OF CHONDROCYTES
Human articular chondrocytes were isolated as
described elsewhere30,31, with a few modifications.
Articular cartilage was obtained at autopsy from different
donors within 24 h post mortem. All donors had died after a
short illness. None of them had been receiving corticoster-
oids or cytostatic drugs. Visually intact cartilage was
sampled from the femur condyles, diced in small fragments
and digested in a spinner bottle. All enzymatic solutions
were made in Dulbecco’s modified Eagle’s medium
(DMEM; GIBCO BRL, Grand Island, NY) with antibiotics
and antimycotics (penicillin 10 U/ml; streptomycin 10 mg/
ml; fungizone 0.025 mg/ml; GIBCO BRL), 0.002 M/ml
L-glutamine and 10% of fetal calf serum (FCS, GIBCO
BRL) when specified. Diced cartilage was treated with
0.25% of sheep testes hyaluronidase (Sigma, St Louis,
MO) in DMEM for 120 min at 37°C followed by 0.25% of
pronase (Streptomyces griseus Pronase E; Sigma) in
DMEM for 90 min at 37°C. The cartilage was then washed
twice with DMEM containing 10% FCS and stored over-
night in the same incubation medium at 37°C. The tissue
was solubilized next day following 3–6 h 0.25% colla-
genase (Clostridium histolyticum; Sigma) treatment in
DMEM with 10% FCS at 37°C. Cells were then washed,tested for viability (Trypan Blue exclusion test) and
counted. Usually, 150×106 chondrocytes could be obtained
from femoral condyles of one individual. More than 95% of
the cells were viable after isolation.CHONDROCYTES IN AGAROSE CULTURE
Chondrocytes were cultured in gelled agarose as pre-
viously described32 with some modifications33,34. Three
percent agarose (ultralow gelling temperature agarose,
Sigma) in distilled water was autoclaved twice for 15 min
and stored at 4–8°C before use. Cryotubes (3.8 ml, Nunc)
were coated with 100 l of this 3% agarose and the coating
was then allowed to gel at 4–8°C. Chondrocyte suspension
cultures were established in 1.5% agarose concentrations.
Three percent (double concentrated) agarose gel was
melted before use, kept at 37°C and mixed with an equal
volume of 2×DMEM (for 50 ml of 2×DMEM: 1.337 g of
lyophilized DMEM, 0.37 g NaHCO3 and 5 mg of ascorbate
in 40 ml distilled water and 10 ml FCS; to sterilize through
a 0.22 m pore membrane filter) to give the desired
concentration of agarose in DMEM with 10% of FCS.
Chondrocyte suspension was added to soluble agarose
in DMEM with a volume ratio of 1:10. Coated cryotubes
were filled with 300 l of chondrocytes/agarose suspension
and kept at 4–8°C for 15 min to allow the agarose to gel.
The final cell density was approximately 1.0×106 chondro-
cytes per culture. The culture tubes were filled with 3 ml
DMEM containing 10% FCS and 50 g/ml of freshly dis-
solved ascorbate, and placed in an incubator at 37°C under
5% CO2. Nutrient media were replaced twice a week.EXPOSURE TO IL-1
After 14 days of culture, IL-1 (recombinant human
IL-1; R&D Systems Ltd, Abingdon, U.K.) was added to the
fresh media at 5, 50 and 100 pg/ml concentrations for a
4-day incubation. Cultures without IL-1 were used as
controls.MEASUREMENT OF 35S-AGGRECAN
During the last 48 h of the IL-1 treatment period,
35Sulfate was added to the media at a concentration of
10 Ci/ml. After conclusion of the experiments, the nutrient
media of the 35S-labeled chondrocyte cultures were
removed. The agarose was dissolved with 2.0 ml of
50 U/ml agarase (agarose 3-glycanohydrolase from
Pseudomonas Atlantica, Sigma) in phosphate buffered
saline (PBS, GIBCO BRL) at 37°C for 1 h. The digest was
then centrifuged at 800 g for 10 min and the supernatant
containing the 35S-labeled aggrecans, which accumulated
in the artificial ITM, was harvested. The pellet with the
chondrocytes and their CAM was washed with PBS and
resuspended in 2.0 ml of 4 M guanidinium chloride with
proteinase inhibitors (0.1 M -amino-n-caproic acid, 0.01 M
EDTA, 0.005 M benzamidine chloride and 0.01 M methyl-
sulphonylfluoride)35 in PBS for 48 h to extract the aggre-
cans of the CAM. The extracts were centrifuged at 800 g
during 15 min and the clear supernatant was recovered.
The nutrient media, agarose digests and the CAM extracts
were desalted through Sephadex G25 (Pharmacia,
Uppsala, Sweden) chromatography gels in 0.067 M
phosphate (K2HPO4/Na2HPO4), pH 6.8, containing
0.01 M Na SO , to separate 35S-labeled aggrecansdecreases in vitro TIMP-1 synthesis. It suppresses the
expression of type II collagen10 and the synthesis of
aggrecan11,12 and is a potent inhibitor of chondrocyte
proliferation13. Furthermore, IL-1 induces the synthesis of
prostaglandins14,15.
The standard method to analyze the metabolism of the
ECM is to assess the incorporation of a radioactive precur-
sor into this matrix during a fixed period of incubation.
35Sulfate is commonly used to label aggrecans16 since one
out of every two sugars along the length of the gly-
cosaminoglycan chains is sulfated. More than 95% of this
precursor is incorporated into aggrecan. The labeled tissue
is then extracted and the incorporated isotope is separated
from the free isotope through chromatography17 or precipi-
tation18. The principles are nearly the same where HA and
collagen synthesis are assayed with radioactive tracer
methods. The precursor for HA can be 3H-glucosamine19,
and for collagen 3H-proline20.
Flow cytometry, a widely accepted technique to assess
phenotype and function of circulating lymphomyeloid cells,
has been used to investigate some characteristics of articu-
lar cartilage cells. Isolated chondrocytes have been tested
for their HLA class I and II antigens21, cytokine recep-
tors22,23, cellular adhesion molecules24,25, intracellular
cytokines26 and cell cycle characteristics27,28. Since the
CAM of the chondrocytes is well preserved when non-
proteolytic isolation procedures are used to obtain these
cells from a culture environment, we have been able to
analyze some of the ECM molecules located around the
chondrocytes29. The mean fluorescence intensity (MFI) of
the antibody-labeled cells is a parameter reflecting the
density of these ECM molecules in the CAM. In this study
we have used a flow cytometric assay of the cell MFI to
estimate the expression of aggrecan, HA and type II
collagen in the CAM. The amount of cellbound aggrecan
was estimated by flow cytometry (chondrocyte MFI),
35Sulfate incorporation methods and ELISA. The results
obtained with the three assays were compared.2 4
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radioactivity by an online liquid scintillation counter.
Considering the volumes of the aliquots that ultimately
were chromatographied, the volume of the culture samples
(nutrient medium, agarose digest and cell-associated
matrix extract), the specific activity of the incubation
medium, the decay of 35Sulfate, the labeling period in hours
and the numbers of cells per culture, sulfate incorporation
was expressed as pg of SO4 incorporated per 1×106
chondrocytes per hour as described36.MONOCLONAL ANTIBODIES AND HYALURONAN BINDING PROTEIN
FOR FLOW CYTOMETRY
Mouse anti-human chondrocyte-specific aggrecan
monoclonal antibody (Mab) (clone 4D11-2A9, IgG1, Bio-
source Europe, Nivelles, Belgium), shown to react
specifically with the G1-domain of the invariable
hyaluronan-binding region of the human aggrecan mol-
ecule, was used to detect the aggrecan in the chondrocyte
CAM. Mouse anti-human type II collagen Mab (clone
II-4C11, IgG1, ICN Biochemicals, Ohio, U.S.A.) was chosen
to detect type II collagen. Both these antibodies were
conjugated with FITC (Fluorescein isothiocyanate, Isomer
I, Sigma), as described elsewhere29 and used in a direct
immunofluorescent staining protocol for flow cytometry.
FITC-labelled isotype matched mouse IgG1 (Becton
Dickinson) was used as a negative control when these
ECM molecules were tested. Biotinylated hyaluronic acid
binding protein (bHABP) was a kind gift from Dr J. Melrose
(Raymond Purves Research Laboratories, University of
Sidney, Australia) and was used to trace hyaluronan in the
CAM. Binding of bHABP to hyaluronan in the CAM was
followed by a second-step FITC-avidin (Becton Dickinson)
staining. FITC-conjugated mouse anti-CD44 (IgG1, Becton
Dickinson) was used to study the expression of CD44 on
the chondrocyte plasma membrane.PREPARATION OF CHONDROCYTES FOR FLOW CYTOMETRY
Samples of the chondrocytes with their CAM were
obtained from cultures after agarase digestion as described
above. The agarase digestion of the agarose gel has been
shown not to influence the detection of the matrix mole-
cules around the cell29. About 2×105 chondrocytes were
resuspended in 100 l PBS, containing 0.1% sodium azide
and 0.2% bovine serum albumin, and incubated with 20 l
of FITC-conjugated Mabs (50 g/ml) against aggrecan,
type II collagen or CD44 for 30 min in the dark at 4°C. The
negative controls were incubated with the same amounts
of control FITC-IgG under identical conditions. To test
hyaluronan, the cells were incubated with 20 l of 50 g/ml
bHABP for 30 min. After washing with PBS, 4 l of FITC-
avidin solution were added for another 30 min at 4°C in the
dark. After incubation with the appropriate reagents, the
cells were washed with PBS and resuspended in 300 l of
PBS with sodium azide and albumin before flow cytometer
analysis.
In order to exclude the possibility that cellbound matrix
molecules impair the detection of cell membrane antigens
(e.g. CD44), a series of chondrocytes were pre-treated with
5 units/ml hyaluronate lyase (Streptomyces Hyalurolyticus,
Sigma) in PBS for 1 h at 37°C prior to labeling with
CD44-FITC. CD44 chondrocyte MFI after removal of the
CAM aggrecan/HA complexes was compared with CD44
MFI of untreated chondrocytes.FLOW CYTOMETRY ANALYSIS
Stained cells were analyzed on a flow cytometer
(FACSort, Becton Dickinson, San Jose, CA, U.S.A.) with
CELLQuest software. From each sample, 15,000 events
were analyzed. Dead cells were excluded by Propidium
Iodide (PI, Sigma) staining. PI binds to DNA in dead cells
with an unintact plasma membrane. Cells were gated on
forward and side scatter to exclude debris and cell aggre-
gates. The flow cytometric setting was identical throughout
all the study. To calculate the mean fluorescence intensity
(MFI) of cells staining with the antigen-specific FITC-Mabs,
the interface channel for positivity was set at the point
where less than 2% of the control fluorescence (cells
exposed to isotype matched FITC-mouse IgG) was posi-
tive. The mean MFI of the positive cell population was used
to quantify the presence of the ECM molecules in the CAM
and the expression of CD44 on the plasma membrane.
For comparison between experiments, Quantum Simply
Cellular Microbeads (Sigma) were used to calibrate the
fluorescence scale of the flow cytometer.ELISA FOR CAM AGGRECAN
After their isolation from the agarose gel, aggrecan in the
CAM of the chondrocytes was extracted with 4 M guanidi-
nium chloride. The aggrecan content of the CAM was
measured using a commercial enzyme amplified sensitivity
immunoassay kit (PG-EASIA Kit, Biosource Europe,
Nivelles, Belgium) according to the manufacturer’s instruc-
tions. The minimum detectable concentration by the EASIA
kit was 0.9 ng/ml.DNA MEASUREMENT
Chondrocyte survival and proliferation in agarose was
followed by measurement of the DNA content in the cul-
tures after the 2-week culture period. DNA content was
assayed as described37 using the enhancement of fluo-
rescence of trisbenzimidazole (Hoechst 33258) when the
latter binds to double stranded DNA38. Therefore, the
agarose cultures were liquefied by sonication over 5 min
(MSE ultrasonicator, type 5.65; power set at 100 Watt).
Hoechst dye in PBS was mixed with the liquefied agarose
at a final concentration of 1 g/ml. The fluorescence was
measured in a Hoefer dyna quant 200 fluorometer, using
double-stranded calf thymus DNA (Sigma) in liquefied
agarose as a standard.STATISTICS
Each test was performed in three identical cultures to
allow calculation of mean values ±1 S.D. Differences
between IL-1-treated groups and the controls were ana-
lyzed with the Student’s t-test. Differential responses in the
whole donor population were tested with the Wilcoxon rank
sum test. One-way ANOVA was used to compare the
IL-1-induced decreases in expression of aggrecan,
hyaluronan and type II collagen in the CAM and to compare
the results obtained by the different analytical methods.
The significance level for all tests was set at P=0.05.
Results
EFFECTS OF IL-1 ON 35SULFATE INCORPORATION INTO
AGGRECAN
35Sulfate was used as radioactive precursor to investi-
gate the effects of IL-1 on aggrecan metabolism by the
chondrocytes obtained from a 63-year-old female donor.
The cells were cultured in gelled agarose and after the
culture period the amounts of 35S-labeled aggrecans
recovered from the CAM, the ITM (the solubilized agarose)
and of the nutrient medium (MED) were quantiﬁed. The
amounts of aggrecans in these three domains were
expressed as picograms of sulfate incorporated in aggre-
can per 1×106 chondrocytes/h (Table I). Proportions of
radiolabeled aggrecans recovered in the CAM, ITM and in
the nutrient media of the control cultures were calculated
from these data and amounted to 19.4%, 72.5% and 9.0%,
respectively (Fig. 1).
As expected, IL-1 provoked a signiﬁcant and dose-
dependent decrease in the mean values for aggrecan
present in the CAM and in the ITM. The amounts of MED
aggrecans also decreased at the lower IL-1 doses. How-
ever, higher amounts of aggrecan were found in the MED
when the cells had been exposed to 100 pg/ml of IL-1
(Table I).
A release of aggrecans from the CAM to the other
extracellular matrix domains was illustrated by the ﬁnding
of a more pronounced percentage decrease in aggrecan
content in the CAM than in the ITM (Table I; %V). Similarly,
the proportions of 35S-aggrecans (related to the total
amount of aggrecan present in the three compartments
of the extracellular matrix) decreased in the CAM and
increased in the ITM, indicating a shift of aggrecans
from the CAM to the ITM under the effect of 5–50 pg/ml of
IL-1 (Fig. 1). Obviously, the increase in the amounts of
aggrecan recovered in the nutrient media at the highest
concentrations of IL-1 also resulted from catabolic events
occurring around the cultured chondrocytes.
FLOW CYTOMETRIC ANALYSIS OF CAM AGGRECAN, TYPE II
COLLAGEN AND HYALURONAN
Chondrocyte samples from ﬁve donors (F63, F28, M23,
M59 and M47) were analyzed for the expression of ECM
molecules. After a 4-day incubation with or without IL-1,
the chondrocytes cultured in agarose were liberated from
the gel using 50 U/ml agarase. The living cells, gated on
the dot blots after PI staining, were analyzed for their
MFI after having reacted with Mabs against aggrecan and
type II collagen. bHABP was used to detect HA in the
CAM of the chondrocytes.
Representative ﬂow cytometry histograms are shown in
Fig. 2. The MFI of the positive cell population was used to
quantify the amounts of the ECM molecules in the CAM. As
compared with the control cells, all three ECM molecules in
the IL-1-treated chondrocytes obtained from the ﬁve
donors were down-regulated. Mean values obtained in
Table I
Accumulation and release of 35S-aggrecan in the ECM compart-
ments
Mean±1 S.D. P value %V
In the CAM
Controls 6831.0±900.0 100.0
IL-1 5 pg/ml 3091.3±178.9 0.002 45.3
50 pg/ml 1336.0±212.4 0.0005 19.6
100 pg/ml 883.2±95.0 0.0003 12.9
In the ITM
Controls 25160.0±2788.0 100.0
IL-1 5 pg/ml 12818.0±714.0 0.002 50.9
50 pg/ml 6358.0±68.0 0.0003 25.3
100 pg/ml 4896.0±340.0 0.0002 19.5
In the medium
Controls 3173.4±481.6 100.0
IL-1 5 pg/ml 885.8±60.2 0.001 27.9
50 pg/ml 713.8±8.6 0.0009 22.5
100 pg/ml 1745.8±533.2 0.03 55.0
Total aggrecan
Controls 35252.1±2312.1 100.0
IL-1 5 pg/ml 16799.8±712.6 0.001 47.7
50 pg/ml 8404.9±150.4 0.001 23.8
100 pg/ml 7526.9±497.8 0.0008 21.4
Donor: F63; data are expressed as picogram of 35sulfate incor-
porated in aggrecan by 106 cells/h; %V: percentage value; CAM:
cell-associated matrix; ITM: interterritorial matrix.
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Fig. 1. Proportions of 35S-labeled aggrecan as related to the total
amounts of 35S-aggrecan present in the three compartments of the
extracellular domain. Med: nutrient medium, itm: interterritorial
matrix, cam–tm: cell-associated matrix–territorial matrix. Abscissa:
IL-1 expressed in pg/ml of nutrient medium. Ordinate: percentage
of 35S-aggrecan.
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triplicate cultures are listed in Table II. The standard devia-
tions for the values obtained illustrate the reproducibility of
the ﬂow cytometry assays. The effects of IL-1 were dose
dependent. The most relevant changes in CAM aggrecan,
HA and type II collagen were induced by IL-1 at concen-
trations of 5 and 50 pg/ml. At 50 pg/ml, IL-1 reduced the
MFI for aggrecan, for HA and for type II collagen to
approximately 55%, 55% and 79% of the original values,
respectively (Table II: %V). An increase of the amount of
IL-1 to 100 pg/ml did not provoke further signiﬁcant
decreases in the expression of these CAM extracellular
matrix macromolecules (Fig. 3). The expression of CAM
aggrecan and HA was most sensitive to the effect of IL-1.
The IL-1-induced change in cellbound aggrecan agreed
with that of HA, but not with that of type II collagen (Fig. 3).
EFFECTS OF IL-1 ON THE EXPRESSION OF CD44 AND ON
CHONDROCYTE PROLIFERATION
Since the presence of aggrecan and HA in the CAM
could have been inﬂuenced by possible IL-1-induced
changes in the expression of CD44, the presence of this
receptor outside the cell was also assessed. IL-1 did not
alter the expression of CD44 on the plasma membrane
(Table III). Furthermore, the detection of CD44 on the
plasma membrane was not hampered by the presence of
aggrecan/HA complexes in the chondrocyte pericellular
matrix. MFI for CD44 did not increase after exposure
of the chondrocytes to Streptomyces Hyalurolyticus
hyaluronidase while this enzyme was shown to completely
remove aggrecan from the cellbound matrix (Table IV).
The DNA content of each culture of donor F63 was
tested to assess the eventual inﬂuences of IL-1 on cell
proliferation in this culture system. IL-1 treated cells did
not show any differences in cell proliferation when
compared with untreated cells [Table III, Fig. 3(A)].
QUANTIFICATION OF CAM AGGRECANS—FLOW CYTOMETRY
VERSUS 35S-INCORPORATION AND ELISA
The techniques of ﬂow cytometry and 35S-incorporation
to quantify CAM aggrecan were compared on chondro-
cytes obtained from the 63-year-old female and from a
23-year-old male donor. The cells were maintained in
agarose under identical experimental protocols for both
methods. IL-1 provoked a signiﬁcant and dose-dependent
decrease in the expression of aggrecan in the CAM of the
cells obtained from both donors (Tables I and II). Both
methods appeared to assess identical events when the
chondrocytes of donor M23 were concerned [Fig. 3(B)],
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Fig. 2. Flow cytometry histograms of anti-aggrecan Mab-stained
chondrocytes (Donor: M47). (A) Without exposure to IL-1; (B)
exposed to 100 pg/ml IL-1. Abscissa: ﬂuorescence intensity;
Ordinate: chondrocyte counts. Left curves: negative controls; right
curves: stained with anti-aggrecan Mab. Arrows indicate mean
ﬂuorescence intensity (MFI) of the anti-aggrecan Mab-stained cell
population.
Table II
Flow cytometric analysis (MFI) of the effect of IL-1 on cell-associated aggrecan, type II collagen and hyaluronan
F63
Mean±1 S.D.
F28
Mean±1 S.D.
M23
Mean±1 S.D.
M47
Mean±1 S.D.
M59
Mean±1 S.D.
Median
(25%–75% quartile)
%V
Aggrecan
Controls 575.4±13.8 418.2±33.2 542.2±22.9 564.3±31.8 604.1±58.7 564.3 (512.2–582.6) 100.0
IL-1 5 pg/ml 422.1±15.8* 359.5±48.2 358.0±41.9* 441.7±43.6* 481.7±9.3* 422.1 (359.1–451.7) 74.8
50 pg/ml 288.2±11.8* 307.9±34.8* 237.3±43.0* 337.8±61.0* 374.8±39.6* 307.9 (275.5–347.1)† 54.6
100 pg/ml 272.1±13.6* 263.4±13.9* 167.1±3.8* 254.7±22.0* 239.3±39.3* 254.7 (221.3–265.6)† 45.1
Type II collagen
Controls 14.7±1.0 10.8±1.0 11.5±0.4 12.0±1.4 16.5±1.3 12.0 (11.3–15.2) 100.0
IL-1 5 pg/ml 13.1±0.5 8.9±1.2 8.9±0.9* 10.8±0.1 13.7±1.1* 10.8 (8.9–13.3) 90.0
50 pg/ml 10.8±1.9* 7.9±0.6* 7.8±1.3* 9.5±0.2* 11.9±0.4* 9.5 (7.9–11.1) 79.2
100 pg/ml 10.3±0.7* 7.5±1.3* 7.7±1.2* 8.4±0.5* 10.4±0.4* 8.4 (7.7–10.3)† 70.0
Hyaluronan
Controls 32.5±2.0 n.d. n.d. 44.1±5.6 51.0±4.9 44.1 (35.4–49.3) 100.0
IL-1 5 pg/ml 27.1±1.2* n.d. n.d. 32.1±3.4* 41.8±1.8* 32.1 (28.4–39.4) 72.8
50 pg/ml 19.3±2.5* n.d. n.d. 24.4±3.8* 36.9±3.1* 24.4 (20.6–33.8) 55.3
100 pg/ml 18.1±0.2* n.d. n.d. 18.7±1.3* 26.4±5.4* 18.7 (18.3–24.5) 42.4
Mean±1 S.D.: mean value±1 standard deviation; median (25%–75% quartile): median with 25% and 75% quartiles of the mean values
obtained from the ﬁve donors; %V: percentage value; n.d.: not done; *: signiﬁcantly different from the controls (Student’s test); †: signiﬁcantly
different from the controls (Wilcoxon’s test).
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but this was not the case in the CAM of donor F63
[Fig. 3(A)]. The Mab used in the ﬂow cytometry technique
measures the amounts of aggrecan protein core, whereas
35S-incorporation quantiﬁes the glycosaminoglycan content
of the same macromolecule and the effects of IL-1 on both
these variables are not of the same magnitude.
ELISA for aggrecan in the CAM was carried out in donor
M47 and M59. After exposure to IL-1, CAM aggrecan
decreased dose-dependently in the cultures obtained from
both these donors (Table V). An identical procedure was
used to prepare chondrocytes for ﬂow cytometry and for
ELISA to quantify the CAM aggrecans. The anti-aggrecan
Mab used in ﬂow cytometry was the same as the detection
Mab used in the ELISA procedure. Analysis of the IL-1-
induced changes in CAM content of the chondrocytes
obtained from these two donors showed a close agreement
between the two methods [Fig. 3(C), (D)]. A signiﬁcant
correlation was observed when the aggrecan MFI (ﬂow
cytometry) and aggrecan absolute contents (ELISA) were
compared under different doses of IL-1 (Fig. 4). Regres-
sion analysis of MFI values vs g/ml values obtained by the
ELISA method showed that the best ﬁtting curve for the
eight experiments performed corresponded to the linear
function: Y=97.2+35.1X (correlation coefficient R: 0.916,
and P-value: 0.0014). This equation allowed a theoretical
value of aggrecan concentration in the CAM of a chondro-
cyte population with a MFI of 500 in this system to be
calculated at 11.5 g/1×106 isolated cells (Fig. 4).
Discussion
The purpose of these experiments is to explore the
possibilities of ﬂow cytometry in the study of the metabolic
processes occurring in the cell-associated intercellular
matrix of articular chondrocytes. The current method used
to study matrix metabolism is to assess the incorporation of
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Fig. 3. Percentage changes in cell-associated matrix (CAM) compounds. (A) Donor F63; (B) Donor M23; (C) Donor M47; (D) Donor M59.
Mean and 1 standard deviation are given. ——: aggrecan assayed with ﬂow cytometry: changes in mean ﬂuorescence intensity (MFI);
—j—: type II collagen assayed with ﬂow cytometry: changes in MFI; —m—: hyaluronan (HA) assayed with ﬂow cytometry: changes in MFI;
—d—: aggrecan assayed with ELISA; —s—: 35Sulfate incorporated into aggrecan; *: type II collagen MFI signiﬁcantly different from
aggrecan MFI and HA MFI; †: aggrecan MFI signiﬁcantly different from 35S aggrecan; no signiﬁcant difference between aggrecan MFI and
aggrecan assayed with ELISA; no signiﬁcant difference between aggrecan MFI and HA MFI.
Table III
Effect of IL-1 on CD44 expression (MFI) and cell proliferation
CD44 MFI DNA
(ng/culture)
Controls 165.7±2.2 6884.6±409.2
IL-1 5 pg/ml 164.4±10.1 6801.4±347.6
50 pg/ml 171.3±4.2 6788.0±352.4
100 pg/ml 174.1±9.5 6988.6±262.8
Donor: F63; mean±1 standard deviation are given; no signiﬁcant
differences between controls and IL-1 treated samples.
Table IV
Effect of enzymatic removal of CAM aggrecan on the detection of
cell membrane CD44 (MFI)
Aggrecan CD44
Controls 284.6±41.0 260.9±5.2
5 U/ml hyaluronate lyase 6.8±0.3 262.6±3.0
Donor: M47 (one week agarose cultures); mean±1 standard
deviation are given.
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a selected radioactive precursor into the neosynthesized
matrix molecules. Radioactive labeling, for instance, allows
the synthesis and turnover of aggrecan to be assessed
using 35Sulfate. However, the list of sulfated ECM proteo-
glycans has emerged over several years and the exact
proportions of 35Sulfate which labels the aggrecan in a
given in-vitro system are difficult to estimate. The use of
monoclonal antibodies certiﬁes the speciﬁcity of the assay.
Furthermore, 35Sulfate indirectly measures the gly-
cosaminoglycan content of the aggrecan, which is not
necessarily the same as the absolute amount of aggrecan.
Monomeric aggrecan obtained from different donors
varies in its molecular size. Decreased galactosamine/
glucosamine ratios reﬂect a shortening of the variable
chondroitin-sulfate bearing region of the aggrecans synthe-
sized by chondrocytes obtained from old donors39. More or
less 35Sulfate can be incorporated in the same amount of
aggrecan recognized by an anti-aggrecan Mab directed
against the hyaluronan binding site of the central protein
core.
The availability of Mabs directed speciﬁcally against
aggrecan, type I and type II collagen has enabled us to
quantify the number of differentiated chondrocytes surviv-
ing in different in-vitro culture systems29. The ﬂuorescence
intensity of the positive cell population, which is due to the
amount of FITC-Mab reacting with the cellbound ECM
molecules, can then be used to quantify the absolute
amounts of the ECM molecules in the CAM.
Chondrocytes cultured in gelled artiﬁcial matrices, e.g.
alginate or agarose, have been shown to accumulate a part
of their newly synthesized ECM molecules in the pericellu-
lar and territorial matrix34,40. These two compartments
deﬁne the CAM. Chondrocytes exert an active metabolic
control over the CAM, whereas the ITM, which is located
further from the cell membrane, is more metabolically
inert7,8. It was previously shown that agarase digestion
of the artiﬁcial agarose matrix allows approximately 80% of
the newly synthesized 35S-aggrecans to be recovered in
the solubilized gel. This 35S-activity represents the newly
synthesized aggrecans of the ITM. About 20% of the
35S-aggrecans thus remain associated with the CAM of the
chondrocytes34.
In this study, ﬁve series of chondrocyte cultures were
initiated to investigate the aggrecan and type II collagen
content of the CAM using ﬂow cytometry. In three of these
cultures, the CAM HA content was analyzed. In one series
(F63), the incorporation of 35Sulfate was used to trace
aggrecan in the different ECM compartments and to test
the effects of IL-1 in this laboratory model. The cultures
obtained from M47 and M59 served to compare ﬂow
cytometry and ELISA to study the aggrecan content of
the chondrocyte CAM. The cultures obtained from
F63 and M23 served to compare ﬂow cytometry and
35S-incorporation in the study of the same variable. The
effects of IL-1 were tested after 2 weeks of culture. It has
been shown that chondrocyte numbers remain constant
after this period of in-vitro culture in 1.5% agarose35. As
chondrocytes do not proliferate in this condition, it was not
expected that IL-1 would affect cell numbers in this
system.
In resting chondrocyte cultures, 19.4% of the 35S-activity
was found in the CAM aggrecans. As expected, IL-1-
induced a signiﬁcant reduction of the ECM aggrecans. This
reduction was more pronounced in the CAM than in the
ITM. This proportionally more important decrease in CAM
aggrecan after exposure of the cells to IL-1 illus-
trated IL-1-induced catabolism. Increased proportions of
35S-aggrecans in the ITM and an increase in the relative
amounts of 35S-aggrecans in the supernatant nutrient
medium reﬂected this IL-1-induced release of aggrecans
from the CAM. Careful analysis of the amounts and propor-
tions of 35S-aggrecans in the CAM, the ITM and in the
supernatant nutrient medium thus revealed that the IL-1
induced changes in the content of the ECM were distinctly
different in these three extracellular domains. Depletion of
35S-aggrecans as a consequence of impaired production
rates and catabolism was most obvious in the CAM.
Flow cytometry conﬁrmed the IL-1-induced depression
of cell-associated 35S-aggrecan. In donor M23, exactly the
same depression of CAM aggrecan under exposure to
Table V
Aggrecan content in CAM assayed with ELISA
M47 M59
Mean±1 S.D. P value %V Mean±1 S.D. P value %V
Controls 15.08±1.02 100.0 11.92±1.64 100.0
IL-1 5 pg/ml 10.98±1.46 0.02 72.8 8.91±0.33 0.04 74.8
50 pg/ml 7.21±1.35 0.001 47.8 7.73±0.68 0.01 64.8
100 pg/ml 5.26±1.23 0.0005 34.9 4.66±1.75 0.006 39.1
Data are expressed as g aggrecan/106cells; mean±1 S.D.: mean±1 standard deviation; %V: percentage
value.
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Fig. 4. Regression analysis of chondrocyte mean ﬂuorescence
intensity (MFI) for aggrecan against aggrecan content of the
cell-associated matrix (CAM) (ELISA). Ordinate: MFI; Abscissa:
CAM aggrecan expressed in g/106 cells. Solid line: regression
line; broken lines: 95% conﬁdence interval. Best ﬁtting curve for
the eight experiments performed corresponds to the linear func-
tion: y=97.2+35.1x. R=correlation coefficient. Insert: calculated
values of CAM aggrecan content for 1×106 chondrocytes with
increasing MFI.
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flow cytometry. However, in donor F63 the decrease in
aggrecan, when measured by 35S-incorporation, was
significantly more pronounced than when assayed by
Mab staining. This finding illustrates that the effect of IL-1
on glycosaminoglycan sulfation and content of the aggre-
can does not always match the changes in the amounts of
the aggrecan molecule.
Exactly the same depression of CAM aggrecan under
exposure to IL-1 was obtained when this effect was
assayed by flow cytometry or ELISA. The chondrocyte
preparation procedure and the Mab used to assay CAM
aggrecan in flow cytometry and in ELISA were the same
and the results obtained enabled us to conclude that
identical variables were studied quantitatively.
One of the advantages of flow cytometry ensues from
the fact that the same sample of cells can be used to study
any other CAM molecule. Another component of the CAM
detected in this study was hyaluronan. The hyaluronan
binding protein (HABP), the region of the protein core of the
aggrecan molecule that specifically recognizes hyaluronan,
was used to detect the latter in the CAM. Although HA and
aggrecan are synthesized in different sites in the cell
(monomeric aggrecan is assembled in the Golgi apparatus
and HA is produced on the plasma membrane), the expres-
sion of both ECM macromolecules was shown to be closely
correlated. Both these CAM molecules were equally sup-
pressed and this suppression was not caused by changes
in the expression of CD44. When cultured in conditions
allowing the maintenance of their original phenotype,
chondrocytes synthesize the macromolecules that make up
the aggrecan aggregate in a co-ordinated manner thereby
retaining the relative amounts of each component of this
macromolecular complex41–43. This finding agrees with our
observation that the de novo synthesized hyaluronan in this
in-vitro culture system is exclusively used as a backbone in
the aggrecan aggregate and no free hyaluronan filaments
could be detected in agarose cultures34.
Type II collagen, another ECM substance produced by
differentiated articular chondrocytes was previously shown
to be detected by flow cytometry29,44. Changes in the
relative amounts of type II collagen in the CAM induced by
IL-1 were easily quantified. The expression of type II
collagen and aggrecan did not occur in a co-ordinated
manner.
Flow cytometry enables the expression of different ECM
compounds to be quantified. Steric hindrance by one or
more of the ECM molecules present in the CAM does not
affect the detection of other plasma membrane-associated
epitopes. Values for CD44 remained the same whether or
not aggrecan/HA aggregates were present in the CAM. A
continuously increasing number of specific monoclonal
antibodies enlarge the spectrum of applications offered by
this method. The possibilities of flow cytometry are not
limited by the availability of antigen-specific Mabs. Other
candidates to detect ECM compounds in this assay system
are cytokines or growth factors that can be used to detect
their specific receptors on the plasma membrane. The use
of HABP to visualize cellbound hyaluronan in this study
illustrates these possibilities.References
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